Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05469165 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

Study acronym: CYPRO-MR
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 15, 2023 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date changed from estimate of Sep 2022 to Jun 20, 2023
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 3 of 14 entries
    • Study title shortened, about 6 words
    • Study description expanded, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Laval University
86 trials monitored
See 1 trial at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.
Trial Details
NCT Number NCT05469165
Lead Sponsor Laval University
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions
(from sponsor)		 Ischemic Mitral Regurgitation
Related terms Myocardial Infarction
Enrollment 214 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov